Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Boehringer Ingelheim
Johnson and Johnson
Colorcon
Mallinckrodt
Fuji
QuintilesIMS
Federal Trade Commission

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,034,370

« Back to Dashboard

Which drugs does patent 8,034,370 protect, and when does it expire?

Patent 8,034,370 protects OZURDEX and is included in one NDA.

This patent has sixty-one patent family members in twenty-five countries.
Summary for Patent: 8,034,370
Title:Ocular implant made by a double extrusion process
Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Inventor(s): Shiah; Jane-Guo (Irvine, CA), Bhagat; Rahul (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Nivaggioli; Thierry (Los Altos, CA), Peng; Lin (Palo Alto, CA), Chou; David (Palo Alto, CA), Weber; David A. (Danville, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/931,954
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 8,034,370

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,034,370

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,318,070 Ocular implant made by a double extrusion process ➤ Sign Up
8,034,366 Ocular implant made by a double extrusion process ➤ Sign Up
9,192,511 Ocular implant made by a double extrusion process ➤ Sign Up
8,506,987 Ocular implant made by a double extrusion process ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Teva
Chinese Patent Office
Merck
Farmers Insurance
Cantor Fitzgerald
US Army
McKinsey
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.